ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 
  • Home
  • Congress Archive
    • ISTH 2022 Congress
    • ISTH 2021 Congress
    • ISTH 2020 Congress
  • Resources
  • Search

Idiopathic Thrombocytopenic Purpura: Conventional Prednisolone vs High-dose Dexamethasone

C. Lewis1,2, Z. Ng1,3, C. Grove1,2,3

1Department of Haematology, Sir Charles Gardiner Hospital, Nedlands, Australia, 2University of Western Australia, Faculty of Medicine and Pharmacology, Nedlands, Australia, 3PathWest Laboratory Medicine, Nedlands, Australia

Abstract Number: PB0834

Meeting: ISTH 2021 Congress

Theme: Platelet Disorders, von Willebrand Disease and Thrombotic Microangiopathies » Acquired Thrombocytopenias

Background: Idiopathic thrombocytopenic purpura (ITP) is an autoimmune condition treated with corticosteroids. Traditionally long-term prednisolone (PDN) has been used. Recently high-dose dexamethasone (HD-DXM), 40mg for four days, reported higher rates of complete response (CR) and similar sustained remission (SR). HD-DXM therefore became our first line treatment for acute ITP in 2016.  

Aims: To compare outcomes, including response, retreatment, use of additional therapies and bleeding, for treatment naïve ITP patients managed with conventional PDN versus short course HD-DXM at our institution.  

Methods: Retrospective review of all patients with treatment naïve ITP at Sir Charles Gairdner Hospital from January 1st 2014 to December 31st 2018. Partial response (PR) and CR were defined as rise in platelet count > 30 x 109/L and >100 x 109/L respectively, with at least a two-fold increase from baseline. SR required maintenance for six months. HD-DXM cycles were 10 days, PDN cycles 28 days long.

Results: 44 patients were identified. Initial treatment was PDN in 21, HD-DXM in 19 and four received other therapies. Response to cycle 1 (C1) treatment was 90% in the PDN (81% CR, 43% SR) and 88% in the HD-DXM cohort (59% CR, 35% SR). In C1, 16 patients received intravenous immunoglobulin (IVIG). Eight patients were retreated with HD-DXM: two achieved response, five switched to PDN/alternate therapies and one never responded. Overall, 66% achieved SR with additional therapy required (41%). 20.5% were lost to follow-up or died. Bleeding rate was similar between PDN and HD-DXM cohorts (11 actionable bleeds each). Two HD-DXM patients had major gastrointestinal haemorrhage, resulting in one death.

First cycle data

Subsequent alternative treatments in HD-DXM and PDN cohorts

Conclusions: Similar rates of response were seen between cohorts. Most patients who were retreated with HD-DXM did not respond to HD-DXM alone. Many patients received early IVIG without waiting for steroid response and yet there was still a high rate of clinically actionable bleeding.

To cite this abstract in AMA style:

Lewis C, Ng Z, Grove C. Idiopathic Thrombocytopenic Purpura: Conventional Prednisolone vs High-dose Dexamethasone [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 2). https://abstracts.isth.org/abstract/idiopathic-thrombocytopenic-purpura-conventional-prednisolone-vs-high-dose-dexamethasone/. Accessed November 29, 2023.

« Back to ISTH 2021 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/idiopathic-thrombocytopenic-purpura-conventional-prednisolone-vs-high-dose-dexamethasone/

Simple Search

Supported By:

Takeda logo

ISTH 2022 Congress site

Visit the official web site for the ISTH 2022 Virtual Congress »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2023 John Wiley & Sons, Inc. All Rights Reserved.
Wiley